NeuroCell-PD: Phase II trial enrollment

In 1999, Genzyme Tissue Repair (GZTR, Cambridge, Mass.) transferred to GENZ its 50 percent interest in a NeuroCell joint venture with DCRN, and under that agreement GZTR is scheduled to repay $20 mil...